A Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of BC008-1A Injection in Subjects with Recurrent CNS WHO Grade 4 Glioma.
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs BC008 1A (Primary)
- Indications Glioma
- Focus Adverse reactions
- Sponsors Sichuan Luzhou Buchang Biopharmaceutical
- 20 Jan 2025 New trial record